This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
This rating reflects Lupin's leadership in environmental transparency and performance
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Subscribe To Our Newsletter & Stay Updated
